{
    "paper_id": "0b374087b8c4717138a5475fb96ef1c43d457a4c",
    "metadata": {
        "title": "SARS-CoV-2 nucleoprotein for diagnosis of COVID-19 due to the Omicron 3 variant 4",
        "authors": [
            {
                "first": "Paula",
                "middle": [],
                "last": "De Michelena",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "INCLIVA Health Research Institute",
                    "location": {
                        "addrLine": "8 Valencia",
                        "country": "Spain"
                    }
                },
                "email": ""
            },
            {
                "first": "\u2020",
                "middle": [],
                "last": "",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Ignacio",
                "middle": [],
                "last": "Torres",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "INCLIVA Health Research Institute",
                    "location": {
                        "addrLine": "8 Valencia",
                        "country": "Spain"
                    }
                },
                "email": ""
            },
            {
                "first": "\u00c1ngela",
                "middle": [],
                "last": "Ramos-Garc\u00eda",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Victoria",
                "middle": [],
                "last": "Gosalbes",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Primary Health Directorate",
                    "location": {
                        "settlement": "Valencia",
                        "country": "Spain"
                    }
                },
                "email": ""
            },
            {
                "first": "Nidia",
                "middle": [],
                "last": "Ruiz",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Health Care center Serrer\u00eda",
                    "location": {
                        "settlement": "Valencia",
                        "country": "Spain"
                    }
                },
                "email": ""
            },
            {
                "first": "Ana",
                "middle": [],
                "last": "Sanmart\u00edn",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Primary Health Directorate",
                    "location": {
                        "settlement": "Valencia",
                        "country": "Spain"
                    }
                },
                "email": ""
            },
            {
                "first": "Pilar",
                "middle": [],
                "last": "Botija",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Primary Health Directorate",
                    "location": {
                        "settlement": "Valencia",
                        "country": "Spain"
                    }
                },
                "email": ""
            },
            {
                "first": "Sandrine",
                "middle": [],
                "last": "Poujois",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "INCLIVA Health Research Institute",
                    "location": {
                        "addrLine": "8 Valencia",
                        "country": "Spain"
                    }
                },
                "email": ""
            },
            {
                "first": "Dixie",
                "middle": [],
                "last": "Huntley",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "INCLIVA Health Research Institute",
                    "location": {
                        "addrLine": "8 Valencia",
                        "country": "Spain"
                    }
                },
                "email": ""
            },
            {
                "first": "Eliseo",
                "middle": [],
                "last": "",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Albert",
                "middle": [],
                "last": "",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "David",
                "middle": [],
                "last": "Navarro",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "INCLIVA Health Research Institute",
                    "location": {
                        "addrLine": "8 Valencia",
                        "country": "Spain"
                    }
                },
                "email": "david.navarro@uv.es."
            }
        ]
    },
    "abstract": [
        {
            "text": "Objectives: It has been suggested that rapid antigen detection assays (RADT) may 26 perform suboptimally in terms of sensitivity for the diagnosis of SARS-CoV-2 Omicron 27 variant infection. To address this issue, we conducted a prospective study in primary 28 health centers to evaluate the clinical performance of the Panbio\u2122 COVID-19 Ag 29",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Abstract"
        },
        {
            "text": "Rapid Test Device in nasopharyngeal specimens (NP) carried out at the point of care. 30 Methods: We recruited 244 patients (median age, 40 years; range 2-96; 141 female) 31 with clinical suspicion of COVID-19 (232 adults and 12 children). 228/244 patients had 32 been fully vaccinated (two doses) with licensed COVID-19 vaccines prior to 33 recruitment. Most patients (222/244) were SARS-CoV-2 na\u00efve prior to enrollment. 34 Patients were tested by RT-PCR and RADT within 5 days since symptoms onset. 35 Results: 126 patients (51.6%) tested positive by both RT-PCR and RADT, 90 patients 36 (36.8%) returned negative results by both assays and 28 patients (11.4%) yielded 37 discordant results (RT-PCR+/RADT-). No patients tested RT-PCR-/RADT+. Overall 38 specificity and sensitivity of RADT was 100% (95% CI, 95.9-100%) and 81.8% (95% 39 CI, 75-87.1%) respectively. The sensitivity of the assay increased from 79.6% (95% CI, 40 66.4-88.5) when considering specimens collected at days 0-1 after symptoms onset, to 41 86.4% (95% CI, 66.7-95.3) when grouping the specimens obtained on days 4-5. 42 : medRxiv preprint 104 and RADT and 90 patients (36.8%) returned negative results by both assays. In turn, 28 105 patients (11.4%) yielded discordant results (RT-PCR+/RADT-). No patients tested RT-106 PCR-/RADT+. Concordance between the results provided by the two assays was good 107 (\u03ba, 0.78; 95% CI, 0.69-0.85). Importantly, time to specimen collection was comparable 108 (P=0.69) between RT-PCR+/RADT+ and RT-PCR+/RADT-patients (median 2 days; 109 range, 0-5). 110",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Abstract"
        },
        {
            "text": "Overall specificity and sensitivity of RADT was 100% (95% CI, 95.9-100%) and 111 81.8% (95% CI, 75-87.1%) respectively. As shown in Table 1 , RADT assay sensitivity 112 increased in parallel with SARS-CoV-2 RNA load, reaching 95.6% in specimens with 113 viral loads \u2265 7.5 log10 copies/ml (C T , \u2264 20). Interestingly, the sensitivity of the assay 114 increased from 79.6% (95% CI, 66.4-88.5) when considering specimens collected at 115",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 132,
                    "end": 139,
                    "text": "Table 1",
                    "ref_id": null
                }
            ],
            "section": "Abstract"
        }
    ],
    "body_text": [
        {
            "text": "Keywords: SARS-CoV-2, Omicron variant, rapid antigen assay, COVID-19, field 46 performance study",
            "cite_spans": [],
            "ref_spans": [],
            "section": ""
        },
        {
            "text": "A number of commercially available rapid antigen detection tests (RADT) targeting the 49 SARS-CoV-2 nucleocapsid protein (NP) have been shown to display a sensitivity of 50 over 80% compared to RT-PCR assays for diagnosis of SARS-CoV-2 infection in 51 symptomatic individuals, provided that testing is conducted within one week after 52 symptoms onset [1] . These RADT were optimized for detection of the ancestral Wuhan-53",
            "cite_spans": [
                {
                    "start": 352,
                    "end": 355,
                    "text": "[1]",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "INTRODUCTION 48"
        },
        {
            "text": "Hu-1 variant, and the emergence of SARS-CoV-2 variants which incorporate non-54 synonymous mutations within the amino acid sequence of NP may impact on the 55 diagnostic efficiency of RADT. In this context, two studies [2, 3] showed that the 56 Panbio\u2122 COVID-19 Ag Rapid Test Device (Abbott Diagnostic GmbH, Jena, Germany) 57 had decreased sensitivity for detection of SARS-CoV-2 Alpha (B.1.1.7) variant 58 compared to non-alpha lineages. As in many other countries, the SARS-CoV-2 Omicron 59 variant has overtaken the Delta variant and currently dominates in Spain ",
            "cite_spans": [
                {
                    "start": 219,
                    "end": 222,
                    "text": "[2,",
                    "ref_id": null
                },
                {
                    "start": 223,
                    "end": 225,
                    "text": "3]",
                    "ref_id": null
                },
                {
                    "start": 560,
                    "end": 565,
                    "text": "Spain",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "INTRODUCTION 48"
        },
        {
            "text": "We collected two NPs per patient, one of which (provided by the manufacturer) was 80 used for RADT while the other was placed in 3 mL of universal transport medium 81 is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "SARS-CoV-2 testing 79"
        },
        {
            "text": "The copyright holder for this preprint this version posted February 2, 2022. As expected, median viral RNA load was significantly higher (P<0.0001) in RT-121 PCR+/RADT+ specimens than in those returning RT-PCR+/RADT-results (Fig. 1) . 122",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 224,
                    "end": 232,
                    "text": "(Fig. 1)",
                    "ref_id": "FIGREF2"
                }
            ],
            "section": "(which was not certified by peer review)"
        },
        {
            "text": "The SARS-CoV-2 Omicron variant carries one or more mutations in the NP gene 124 Omicron and other variants of concern was not possible due to the absolute dominance 158 of the former at the time of study. Third, no cell cultures were performed for specimens 159 returning discordant RT-PCR/RADT results. Fourth, the small number of children, 160 SARS-CoV-2-experienced and unvaccinated individuals enrolled precluded conducting 161 robust subanalyses for these population groups. 162",
            "cite_spans": [],
            "ref_spans": [],
            "section": "DISCUSSION 123"
        },
        {
            "text": "In summary, we found the Panbio\u2122 COVID-19 Ag Rapid Test Device to perform well 163 as a point-of-care test for early diagnosis of COVID-19 due to the Omicron variant in 164 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "DISCUSSION 123"
        },
        {
            "text": "The copyright holder for this preprint this version posted February 2, 2022. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "(which was not certified by peer review)"
        },
        {
            "text": "The copyright holder for this preprint this version posted February 2, 2022. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "(which was not certified by peer review)"
        },
        {
            "text": "The copyright holder for this preprint this version posted February 2, 2022. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)",
            "cite_spans": [],
            "ref_spans": [],
            "section": "(which was not certified by peer review)"
        },
        {
            "text": "The copyright holder for this preprint this version posted February 2, 2022. ; . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)",
            "cite_spans": [],
            "ref_spans": [],
            "section": "(which was not certified by peer review)"
        },
        {
            "text": "The copyright holder for this preprint this version posted February 2, 2022. ; https://doi.org/10.1101/2022.02.02.22270295 doi: medRxiv preprint",
            "cite_spans": [],
            "ref_spans": [],
            "section": "(which was not certified by peer review)"
        }
    ],
    "bib_entries": {
        "BIBREF1": {
            "ref_id": "b1",
            "title": "WA Comparison of the Performance of the PanBio COVID-19 Antigen Test in SARS-189",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF2": {
            "ref_id": "b2",
            "title": "CoV-2 B.1.1.7 (Alpha) Variants versus non-B.1.1.7 Variants",
            "authors": [],
            "year": 2021,
            "venue": "Microbiol Spectr",
            "volume": "190",
            "issn": "9",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF3": {
            "ref_id": "b3",
            "title": "Field 194 evaluation of a rapid antigen test (Panbio\u2122 COVID-19 Ag Rapid Test Device) for",
            "authors": [
                {
                    "first": "E",
                    "middle": [],
                    "last": "Albert",
                    "suffix": ""
                },
                {
                    "first": "I",
                    "middle": [],
                    "last": "Torres",
                    "suffix": ""
                },
                {
                    "first": "F",
                    "middle": [],
                    "last": "Bueno",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [],
                    "last": "Huntley",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [],
                    "last": "Molla",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "\u00c1"
                    ],
                    "last": "Fern\u00e1ndez-Fuentes",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF4": {
            "ref_id": "b4",
            "title": "COVID-19 diagnosis in primary healthcare centres",
            "authors": [],
            "year": 2021,
            "venue": "Clin Microbiol Infect",
            "volume": "27",
            "issn": "",
            "pages": "472--479",
            "other_ids": {}
        },
        "BIBREF5": {
            "ref_id": "b5",
            "title": "Discordant SARS-CoV-2 PCR and",
            "authors": [
                {
                    "first": "B",
                    "middle": [],
                    "last": "Adamson",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [],
                    "last": "Sikka",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [
                        "L"
                    ],
                    "last": "Wyllie",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [],
                    "last": "Premsrirut",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        }
    },
    "ref_entries": {
        "FIGREF0": {
            "text": "DeltaSwab Virus, Deltalab, Barcelona, Spain) and delivered to the HCU Microbiology 82 Service for RT-PCR testing. RADT was performed immediately after sampling 83 following the manufacturer's instructions (reading at 15 min). RT-PCRs were carried 84 out within 24 h of specimen collection with the TaqPath COVID-19 Combo Kit 85 (Thermo Fisher Scientific, MS, USA) which targets SARS-CoV-2 ORF1ab, N and S 86 genes. RNA was extracted using the Applied Biosystems\u2122 MagMAX\u2122 87 Viral/Pathogen II Nucleic Acid Isolation Kits coupled with Thermo Scientific\u2122 88 KingFisher Flex automated instrument. The AMPLIRUN\u00ae TOTAL SARS-CoV-2 89 Control (Vircell SA, Granada, Spain) was used as the reference material for SARS-90 CoV-2 RNA load quantification [5], for which purpose RT-PCR cycle threshold (C T ) 91 values returned by amplification of the NP gene were considered. The S-gene dropout 92",
            "latex": null,
            "type": "figure"
        },
        "FIGREF1": {
            "text": ". In line with previous findings from our group [5], RADT sensitivity increased in 146 parallel with SARS-CoV-2 RNA load in NP. Interestingly, the sensitivity of the RADT 147 assay also appeared to increase with time elapsed after symptoms onset, suggesting that 148 vaccine-breakthrough Omicron variant infection may be symptomatic even in the 149 presence of RNA loads below the threshold for viral detection by RADT. Although 150 speculative, this phenomenon may be related to the reduced capability of the Omicron 151 variant to antagonize the host cell interferon response [10]. 152 The limitations of the current study are as follows. First, Omicron subvariant B.1.529.2 153 (BA.2), which lacks the 69-70 deletion, may be incorrectly categorized as such based on 154 the SGTF result; nonetheless, this subvariant could not be identified in sequenced 155 specimens within the study period in our health department. Second, side-by-side 156 clinical performance comparison of the RADT for diagnosis of COVID-19 due to 157",
            "latex": null,
            "type": "figure"
        },
        "FIGREF2": {
            "text": "J, Druce J, Tran T, Batty M, Yoga Y, Fennell M, et al. Assessment of the 207 analytical sensitivity of ten lateral flow devices against the SARS-CoV-Box-Whisker plots depicting RT-PCR cycle threshold values (C T ) (A) and 215 viral RNA loads (B) in nasopharyngeal specimens collected from COVID-19 patients 216 infected with the Omicron variant testing either positive or negative by the Panbio\u2122 217 COVID-19 Ag Rapid Test Device (Abbott Diagnostic GmbH, Jena, Germany).",
            "latex": null,
            "type": "figure"
        },
        "TABREF0": {
            "text": ". It has been 60 suggested that RADT may be less sensitive for detecting the Omicron variant [4], but 61 this assumption lacks support by real-life RADT performance studies. Here, we 62 conducted a prospective study in primary health centers to evaluate the clinical 63 performance of the Panbio\u2122 COVID-19 Ag Rapid Test Device in nasopharyngeal 64 specimens (NP) carried out at the point of care for diagnosis of Omicron variant 65is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)In the current observational prospective study, a convenience sample of 244 patients 69 (median age, 40 years; range 2-96; 141 female) with clinical suspicion of COVID-19, 70 232 of whom were adults (median age, 41 years; range, 17-96) and 12 children (median 71",
            "latex": null,
            "type": "table"
        },
        "TABREF1": {
            "text": "RT-PCR profile was systematically associated with the Omicron variant within the 93 study period, as confirmed by whole-genome sequencing (not shown). 94 Agreement between RAD assay and RT-PCR was assessed using Cohen's Differences between medians were compared using the Mann-Whitney U-test. Two-97sided P values < 0.05 were considered significant. Statistical analyses were performed 98 using SPSS version 25.0 (SPSS, Chicago, IL, USA). 99RESULTS 100Results relevant to interpretation of the data presented herein are as follows.First, 228 101 of the 244 patients had been fully vaccinated (two doses) with licensed COVID-19 102 vaccines prior to recruitment. Second, most patients (222 out of 244) were SARS-CoV-103 days 0-1 after symptoms onset, to 86.4% (95% CI, 66.7-95.3) when grouping the 116 specimens obtained on days 4-5 (SupplementaryTable 1). 117Overall, RADT negative predictive value for an estimated prevalence of 30% and 35% 118 (representative of our Health Department during the study period) was 92.8% (95% CI, 119 85.8-96.5) and 91.1% (95% CI, 82.8-95.6), respectively. 120",
            "latex": null,
            "type": "table"
        },
        "TABREF2": {
            "text": "Del31-33, R203K and G203K) [6] that may impact on the sensitivity of RADT 125 Test Device to display exquisite specificity and acceptable overall sensitivity (81.8%) 140 for Omicron diagnosis, both figures exceeding regulatory agency requirements for 141 temporary approval (at least 98% and 80%, respectively) [1]. In our experience, the 142 clinical performance of the Panbio\u2122 COVID-19 assay for Omicron variant was 143 comparable to previous reports for the Wuhan-Hu-1 G614 variant (100% specificity and 144 sensitivity of 81.4% in non-vaccinated adult patients with a clinical course of <5 days) 145",
            "latex": null,
            "type": "table"
        },
        "TABREF3": {
            "text": "primary healthcare centers. Further studies are warranted to evaluate the performance of 165 this and other RADT for detection of Omicron variant infection in asymptomatic, 166 pediatric and unvaccinated individuals. 167 ACKNOWLEDGMENTS 168 We are grateful to residents and staff at the Microbiology Service of Hospital Cl\u00ednico 169 Universitario and medical and nursing staff at primary health centers (Benimaclet, 170 Serrer\u00eda and Salvador Pau) recruiting patients for the current study. Ignacio Torres (R\u00edo 171 Hortega Contract; CM20/00090) and Eliseo Albert (Juan Rod\u00e9s Contract; JR20/00011) 172 hold contracts funded by the Carlos III Health Institute (co-financed by the European 173",
            "latex": null,
            "type": "table"
        },
        "TABREF4": {
            "text": "; https://doi.org/10.1101/2022.02.02.22270295 doi: medRxiv preprint Supplementary Table 1. SARS-CoV-2 RT-PCR and Panbio\u2122 COVID-19 Ag Rapid Test results in nasopharyngeal specimens collected from COVID-19 patients according to time elapsed since onset of symptoms Panbio\u2122 COVID-19 Ag Rapid Test result in study groups SARS-CoV-2 RT-PCR result No. of positives No. of negatives",
            "latex": null,
            "type": "table"
        },
        "TABREF5": {
            "text": "Overall sensitivity of the Panbio\u2122 COVID-19 Ag Rapid Test Device according to the SARS-CoV-2 RNA load in nasopharyngeal specimens RT-PCR cycle threshold value SARS-CoV-2 RNA load (log 10 copies/ml)",
            "latex": null,
            "type": "table"
        }
    },
    "back_matter": []
}